1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biosimilars Market by Product & Application - Global Forecast to 2020

Various factors have contributed to the rise in demand for biopharmaceutical products such as biologics and biosimilars. Some of these factors include the rising pressure to reduce healthcare expenditure, growing demand for cost-effective alternatives, growing burden of chronic diseases, and growing aging population. Biosimilars are similar versions of their corresponding patented biologic drugs, and are similar with regards to their quality, safety, and efficacy. The global biosimilars market is estimated to be worth $2.29 billion in 2015, and is poised to grow at a CAGR of 22.1% during the forecast period.

This report studies and analyzes the biosimilars market by product and application. On the basis of products, the biosimilars market is segmented into recombinant nonglycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant nonglycosylated proteins market is further segmented into insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormones; whereas, the recombinant glycosylated proteins market is further segmented into erythropoietin, monoclonal antibodies, and follitropin. The recombinant peptides market is segmented into calcitonin and glucagon. The recombinant glycosylated proteins segment is expected to witness the highest growth rate owing to the increased demand for monoclonal antibodies in the treatment of cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. On the other hand, the recombinant nonglycosylated proteins segment accounts for the largest share of the market in 2015. The insulin segment is poised to be the fastest-growing segment of the recombinant nonglycosylated proteins market, growing at a CAGR of 28.1% from 2015 to 2020. Growth in this insulin market is attributed to the rising incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of insulin.

On the basis of applications, the biosimilars market is segmented into oncology, blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and other applications (female infertility, hypoglycemia, myocardial infarction, postmenopausal osteoporosis, and chronic kidney failure).

Geographically, Europe is expected to account for the largest share of the global biosimilars market in 2015 followed by Asia-Pacific. The large share of the European region can be attributed to the rising budgetary pressures to reduce healthcare expenditure, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and government initiatives. On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder its market growth.


The global biosimilars market is highly competitive, with a large number of big and small market players. As of 2014, the global biosimilars market was dominated by Sandoz International GmbH (Germany), Hospira, Inc. (U.S.), and Teva Pharmaceutical Industries Ltd. (Israel). Furthermore, new product launches and expansions are the major strategies adopted by major players to achieve growth in this market.



Reasons to Buy the Report:
From an insight perspective, this research report focused on various levels of analysis—industry analysis (industry trends and Porter’s five forces model), market share analysis of top players, and company profiles, which together comprise and discuss the basic views on the competitive landscape; emerging and high-growth segments in the biosimilars market; and high-growth regions/countries and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms in garnering a greater market share. Firms purchasing the report could use any one or combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.



The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on biosimilar products offered by the top 10 players in the biosimilars market. The report analyzes the biosimilars market by product and application across geographies

- Product Development/Innovation: Detailed insights on research and development activities and new product launches in the biosimilars market

- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various biosimilar products across geographies

- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of leading players in the biosimilars market

Table Of Contents

Biosimilars Market by Product and Application - Global Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKET SEGMENTATION 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.3 MARKET SHARE ESTIMATION 25
2.3.1 KEY DATA FROM SECONDARY SOURCES 25
2.3.2 KEY DATA FROM PRIMARY SOURCES 26
2.3.2.1 Key industry insights 26
2.4 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
3.1 INTRODUCTION 27
4 PREMIUM INSIGHTS 31
4.1 OVERALL BIOSIMILARS MARKET 31
4.2 BIOSIMILARS MARKET, BY TYPE and REGION 32
4.3 BIOSIMILARS MARKET, BY COUNTRIES 33
4.4 RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET, BY TYPE 34
4.5 LIFECYCLE ANALYSIS, BY REGION 34
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 BIOSIMILARS MARKET SEGMENTATION 37
5.2.1 BY PRODUCT 37
5.2.2 BY APPLICATION 37
5.2.3 BY REGION 38
5.3 MARKET DYNAMICS 38
5.3.1 DRIVERS 39
5.3.1.1 Growing pressure to curtail healthcare expenditure 39
5.3.1.2 Increasing demand for biosimilar drugs due to their cost-effectiveness 39
5.3.1.3 Rising incidences of diseases 39
5.3.1.4 Rise in aging population triggers the incidences of chronic disorders 40
5.3.1.5 Strategic collaborations lead to enhance productivity and clinical trial activities for biosimilars 40
5.3.1.6 Increasing government support and initiatives to develop and promote biosimilars 41
5.3.2 RESTRAINTS 42
5.3.2.1 High manufacturing complexities and costs 42
5.3.2.2 Innovative strategies by biologic drug manufacturers 43
5.3.3 OPPORTUNITIES 44
5.3.3.1 Emerging markets 44
5.3.3.2 Untapped indications 44
5.3.3.3 Biologic products set to be off-patent will offer opportunities for biosimilars 44
5.3.4 CHALLENGES 46
5.3.4.1 Stringent regulatory requirements to adversely affect investments in biosimilars 46
5.3.5 BURNING ISSUES 47
5.3.5.1 Product withdrawals provide significant opportunities for new entrants 47
6 INDUSTRY INSIGHTS 48
6.1 INTRODUCTION 48
6.2 PORTER'S FIVE FORCES ANALYSIS 48
6.2.1 THREAT OF NEW ENTRANTS 49
6.2.2 THREAT OF SUBSTITUTES 49
6.2.3 INTENSITY OF RIVALRY 49
6.2.4 BARGAINING POWER OF SUPPLIERS 49
6.2.5 BARGAINING POWER OF BUYERS 50
6.3 KEY PIPELINE PRODUCTS 50
6.4 REGULATORY OUTLOOK 51
6.4.1 NORTH AMERICA 51
6.4.1.1 U.S. 51
6.4.1.2 Canada 51
6.4.2 EUROPE 52
6.4.3 ASIA-PACIFIC 53
6.4.3.1 China 53
6.4.3.2 India 53
6.4.3.3 Japan 53
6.4.3.4 South Korea 53
6.4.4 REST OF THE WORLD 54
6.4.4.1 Brazil 54
6.4.4.2 Mexico 54
6.4.4.3 Argentina 54
6.4.4.4 Saudi Arabia 54
6.5 BIOSIMILARS SERVICES INDUSTRY INSIGHTS 55
6.5.1 INTRODUCTION 55
6.5.2 CONTRACT MANUFACTURING ORGANIZATIONS 55
6.5.3 CONTRACT RESEARCH ORGANIZATIONS 56
6.5.4 OTHER SERVICES (NONCLINICAL and BIOINFORMATICS) 56
7 BIOSIMILARS MARKET, BY TYPE OF PRODUCT 57
7.1 INTRODUCTION 58
7.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS 59
7.2.1 INSULIN 62
7.2.2 RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 63
7.2.3 GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) 64
7.2.4 INTERFERONS 66
7.3 RECOMBINANT GLYCOSYLATED PROTEINS 67
7.3.1 ERYTHROPOIETIN (EPO) 71
7.3.2 MONOCLONAL ANTIBODIES (MABS) 72
7.3.3 FOLLITROPIN 73
7.4 RECOMBINANT PEPTIDES 74
7.4.1 GLUCAGON 77
7.4.2 CALCITONIN 77
8 BIOSIMILARS MARKET, BY APPLICATION 79
8.1 INTRODUCTION 80
8.2 ONCOLOGY 81
8.3 BLOOD DISORDERS 82
8.4 CHRONIC AND AUTOIMMUNE DISEASES 83
8.5 GROWTH HORMONE DEFICIENCY 84
8.6 INFECTIOUS DISEASES 85
8.7 OTHER APPLICATIONS 86
9 BIOSIMILARS MARKET, BY REGION 87
9.1 INTRODUCTION 88
9.2 NORTH AMERICA 91
9.2.1 U.S. 95
9.2.2 CANADA 96
9.3 EUROPE 98
9.3.1 U.K. 101
9.3.2 GERMANY 102
9.3.3 FRANCE 102
9.3.4 SPAIN 103
9.3.5 ITALY 104
9.3.6 REST OF EUROPE 104
9.4 ASIA-PACIFIC 106
9.4.1 CHINA 109
9.4.2 INDIA 110
9.4.3 JAPAN 111
9.4.4 SOUTH KOREA 112
9.4.5 REST OF ASIA-PACIFIC (ROAPAC) 113
9.5 REST OF THE WORLD (ROW) 115
10 COMPETITIVE LANDSCAPE 119
10.1 OVERVIEW 119
10.2 MARKET SHARE ANALYSIS 120
10.3 COMPETITIVE SITUATION AND TRENDS 121
10.3.1 NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS 122
10.3.2 AGREEMENTS AND COLLABORATIONS 122
10.3.3 EXPANSIONS 123
10.3.4 ACQUISITIONS 123
10.3.5 OTHER DEVELOPMENTS 124
11 COMPANY PROFILES 125
(Overview, Financials, Products and Services, Strategy, and Developments)*
11.1 INTRODUCTION 125
11.2 HOSPIRA, INC. 126
11.3 SANDOZ INTERNATIONAL GMBH (A DIVISION OF NOVARTIS INTERNATIONAL AG) 128
11.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 130
11.5 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMANN-LA ROCHE LTD.) 132
11.6 AMGEN 134
11.7 BIOCON LTD. 136
11.8 DR. REDDY'S LABORATORIES 138
11.9 CELLTRION INC. 140
11.10 MYLAN INC. 142
11.11 MERCK KGAA 144

*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.


12 APPENDIX 146
12.1 INSIGHTS FROM INDUSTRY EXPERTS 146
12.2 DISCUSSION GUIDE 147
12.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 150
12.4 AVAILABLE CUSTOMIZATIONS 151
12.5 RELATED REPORTS 152


LIST OF TABLES

TABLE 1 BIOSIMILARS MARKET: MAJOR COLLABORATIONS (2012-2015) 41
TABLE 2 BIOLOGICS GOING OFF-PATENT TO BOOST THE MARKET GROWTH FOR BIOSIMILARS 42
TABLE 3 HIGH MANUFACTURING COMPLEXITIES AND COSTS RESTRAINING THE GROWTH FOR THE BIOSIMILARS MARKET 43
TABLE 4 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY 45
TABLE 5 GROWTH PROSPECTS IN EMERGING MARKETS FUEL THE MARKET GROWTH 45
TABLE 6 STRINGENT REGULATORY REQUIREMENTS IN MAJOR COUNTRIES IS A MAJOR CHALLENGE FOR THE BIOSIMILARS MARKET 46
TABLE 7 BIOSIMILARS IN CLINICAL TRIALS 50
TABLE 8 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA REGION 51
TABLE 9 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES 52
TABLE 10 STATUS OF REGULATORY PATHWAY IN THE ASIA-PACIFIC REGION 53
TABLE 11 STATUS OF REGULATORY PATHWAY IN THE ROW 54
TABLE 12 JOINT VENTURES BETWEEN CMOS and PHARMACEUTICAL COMPANIES FOR BIOSIMILARS 56
TABLE 13 BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2013-2020 ($MILLION) 58
TABLE 14 RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 59
TABLE 15 RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 60
TABLE 16 NORTH AMERICA: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION) 60
TABLE 17 EUROPE: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE,
BY COUNTRY, 2013-2020 ($MILLION) 61
TABLE 18 ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE,
BY COUNTRY, 2013-2020 ($MILLION) 61
TABLE 19 INSULIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 63
TABLE 20 RECOMBINANT HUMAN GROWTH HORMONE MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 64
TABLE 21 LIST OF APPROVED PRODUCTS FROM 2012 TO 2015. 65
TABLE 22 GRANULOCYTE COLONY-STIMULATING FACTOR MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 65
TABLE 23 INTERFERONS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 66
TABLE 24 RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 68
TABLE 25 RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY REGION,
2013-2020 ($MILLION) 69
TABLE 26 NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE,
BY COUNTRY, 2013-2020 ($MILLION) 69
TABLE 27 EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE,
BY COUNTRY, 2013-2020 ($MILLION) 70
TABLE 28 ASIA-PACIFIC: RECOMBINANT NON-GLYCOSYLATED PROTEINS MARKET SIZE,
BY COUNTRY, 2013-2020 ($MILLION) 70
TABLE 29 ERYTHROPOIETIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 71
TABLE 30 MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 73
TABLE 31 FOLLITROPIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 73
TABLE 32 RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 74
TABLE 33 RECOMBINANT PEPTIDES MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 75
TABLE 34 NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 75
TABLE 35 EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 76
TABLE 36 ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 76
TABLE 37 GLUCAGON MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 77
TABLE 38 CALCITONIN MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 78
TABLE 39 BIOSIMILARS MARKET SIZE, BY APPLICATION, 2012-2019 ($MILLION) 80
TABLE 40 BIOSIMILARS MARKET SIZE FOR ONCOLOGY, BY REGION, 2012-2019 ($MILLION) 81
TABLE 41 BIOSIMILARS MARKET SIZE FOR BLOOD DISORDERS, BY REGION,
2012-2019 ($MILLION) 82
TABLE 42 BIOSIMILARS MARKET SIZE FOR CHRONIC AND AUTOIMMUNE DISEASES,
BY REGION, 2012-2019 ($MILLION) 83
TABLE 43 BIOSIMILARS MARKET SIZE FOR GROWTH HORMONE DEFICIENCY,
BY REGION, 2012-2019 ($MILLION) 84
TABLE 44 BIOSIMILARS MARKET SIZE FOR INFECTIOUS DISEASES, BY REGION,
2012-2019 ($MILLION) 85
TABLE 45 BIOSIMILARS MARKET SIZE FOR OTHER APPLICATIONS, BY REGION,
2012-2019 ($MILLION) 86
TABLE 46 BIOSIMILARS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 89
TABLE 47 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY,
2013-2020 ($MILLION) 90
TABLE 48 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY PRODUCT,
2013-2020 ($MILLION) 92
TABLE 49 NORTH AMERICA: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 93
TABLE 50 NORTH AMERICA: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 93
TABLE 51 NORTH AMERICA: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 94
TABLE 52 NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 94
TABLE 53 U.S.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 96
TABLE 54 CANADA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 97
TABLE 55 EUROPE: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION) 99
TABLE 56 EUROPE: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 99
TABLE 57 EUROPE: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 100
TABLE 58 EUROPE: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 100
TABLE 59 EUROPE: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 101
TABLE 60 U.K.: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 101
TABLE 61 GERMANY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 102
TABLE 62 FRANCE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 103
TABLE 63 SPAIN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 103
TABLE 64 ITALY: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 104
TABLE 65 ROE: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 105
TABLE 66 ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION) 107
TABLE 67 ASIA-PACIFIC: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 107
TABLE 68 ASIA-PACIFIC: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 108
TABLE 69 ASIA-PACIFIC: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 108
TABLE 70 ASIA-PACIFIC: BIOSIMILARS MARKET SIZE, BY APPLICATION,
2013-2020 ($MILLION) 109
TABLE 71 CHINA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 110
TABLE 72 INDIA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
TABLE 73 JAPAN: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 112
TABLE 74 SOUTH KOREA: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 113
TABLE 75 ROAPAC: BIOSIMILARS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 114
TABLE 76 ROW: BIOSIMILARS MARKET SIZE, BY PRODUCT, 2013-2020 ($MILLION) 116
TABLE 77 ROW: RECOMBINANT NONGLYCOSYLATED PROTEINS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 116
TABLE 78 ROW: RECOMBINANT GLYCOSYLATED PROTEINS MARKET SIZE, BY TYPE,
2013-2020 ($MILLION) 117
TABLE 79 ROW: RECOMBINANT PEPTIDES MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 117
TABLE 80 ROW: BIOSIMILARS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 118
TABLE 81 RECENT NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS, 2012-2015 122
TABLE 82 RECENT AGREEMENTS AND COLLABORATIONS, 2012-2015 122
TABLE 83 RECENT EXPANSIONS, 2012-2015 123
TABLE 84 RECENT ACQUISITIONS 2012-2015 123
TABLE 85 RECENT OTHER DEVELOPMENTS, 2012-2015 124


LIST OF FIGURES

FIGURE 1 GLOBAL BIOSIMILARS MARKET, BY PRODUCT TYPE 17
FIGURE 2 RESEARCH DESIGN 20
FIGURE 3 TOP-DOWN APPROACH 22
FIGURE 4 BOTTOM-UP APPROACH 22
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION AND REGION 23
FIGURE 6 DATA TRIANGULATION METHODOLOGY 24
FIGURE 7 MARKET SNAPSHOT: RECOMBINANT NONGLYCOSYLATED PROTEINS TO DOMINATE THE MARKET 27
FIGURE 8 ASIA-PACIFIC TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD 28
FIGURE 9 EUROPE TO DOMINATE NONGLYCOSYLATED PROTEINS MARKET DURING
2015-2020 29
FIGURE 10 BIOSIMILAR MARKET: GEOGRAPHIC SNAPSHOT 30
FIGURE 11 BIOSIMILARS MARKET TO GROW AT A HIGH RATE DURING THE FORECAST PERIOD 31
FIGURE 12 RECOMBINANT NONGLYCOSYLATED PROTEINS SEGMENT HELD THE LARGEST MARKET SHARE IN 2014 32
FIGURE 13 GERMANY DOMINATED THE BIOSIMILARS MARKET IN 2014 33
FIGURE 14 INSULIN SEGMENT TO WITNESS HIGHEST GROWTH RATE FROM 2015 TO 2020 34
FIGURE 15 ASIA-PACIFIC TO WITNESS HIGH GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD 34
FIGURE 16 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES and CHALLENGES 38
FIGURE 17 GLOBAL BIOSIMILARS MARKET: PORTER'S FIVE FORCES ANALYSIS 48
FIGURE 18 INSULIN IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD 62
FIGURE 19 ERYTHROPOIETIN IS EXPECTED TO DOMINATE THE MARKET IN THE FORECAST PERIOD 68
FIGURE 20 GLUCAGON WILL CONTINUE TO DOMINATE THE MARKET IN THE FORECAST PERIOD 74
FIGURE 21 ONCOLOGY DOMINATES THE BIOSIMILARS APPLICATIONS MARKET 80
FIGURE 22 GEOGRAPHIC SNAPSHOT (2015): EMERGING MARKETS HOLD SIGNIFICANT GROWTH OPPORTUNITIES 88
FIGURE 23 ASIA-PACIFIC, AN ATTRACTIVE MARKET FOR BIOSIMILARS 89
FIGURE 24 NORTH AMERICA: MARKET SNAPSHOT 91
FIGURE 25 RECOMBINANT PEPTIDES WILL DRIVE THE GROWTH OF THE BIOSIMILAR MARKET IN THE U.S. 95
FIGURE 26 RECOMBINANT GLYCOSYLATED PROTEINS WILL CONTINUE TO HOLD THE LARGEST SHARE IN THE EUROPEAN MARKET 98
FIGURE 27 ASIA-PACIFIC: MARKET SNAPSHOT 106
FIGURE 28 MAJOR PLAYERS ADOPTED THE STRATEGY OF APPROVALS TO ENHANCE THEIR MARKET POSITIONS IN THE BIOSIMILARS MARKET (2012-2015) 119
FIGURE 29 GLOBAL BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2014 120
FIGURE 30 BATTLE FOR MARKET SHARE: NEW PRODUCT LAUNCHES AND REGULATORY APPROVALS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS 121
FIGURE 31 PRODUCT BENCHMARKING FOR TOP 3 PLAYERS 125
FIGURE 32 HOSPIRA, INC.: COMPANY SNAPSHOT 126
FIGURE 33 SANDOZ INTERNATIONAL GMBH: COMPANY SNAPSHOT 128
FIGURE 34 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 130
FIGURE 35 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 132
FIGURE 36 AMGEN: COMPANY SNAPSHOT 134
FIGURE 37 BIOCON LTD.: COMPANY SNAPSHOT 136
FIGURE 38 DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT 138
FIGURE 39 CELLTRION INC.: COMPANY SNAPSHOT 140
FIGURE 40 MYLAN INC.: COMPANY SNAPSHOT 142
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT 144

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.